Track MoonLake Immunotherapeutics Class A Ordinary Shares — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

MoonLake Immunotherapeutics Class A Ordinary Shares MLTX Open MoonLake Immunotherapeutics Class A Ordinary Shares in new tab

16.44 USD
EPS
-3.88
P/B
4.98
ROE
-77.85
Beta
1.19
Key Metrics
Earnings dateAug. 4, 2026
EPS-3.88
Book Value3.52
Price to Book4.98
Debt/Equity39.68
% Insiders9.680%
Estimates
Forward P/E-5.09
Forward EPS-3.45

DCF Valuation

Tweak assumptions to recompute fair value for MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

MoonLake Immunotherapeutics Class A Ordinary Shares Analysis (MLTX)

United States Health Care Stock

Is MoonLake Immunotherapeutics Class A Ordinary Shares a good investment? MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) is currently trading at 16.44 USD.

Earnings Schedule: MoonLake Immunotherapeutics Class A Ordinary Shares is expected to release its next earnings report on Aug. 4, 2026. The market consensus estimate for Forward EPS is -3.45.

Investor FAQ

Does MoonLake Immunotherapeutics Class A Ordinary Shares pay a dividend?

No, it does not currently pay a dividend.

What asset class is MoonLake Immunotherapeutics Class A Ordinary Shares?

MoonLake Immunotherapeutics Class A Ordinary Shares is classified as a Stock.

When is the next earnings date?

The next earnings date is projected to be Aug. 4, 2026. The company currently has a trailing EPS of -3.88.

Company Profile

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion